VERV vs. BEAM, KRYS, CYTK, ZLAB, PTCT, MRUS, ACLX, ACAD, SWTX, and RARE
Should you be buying Verve Therapeutics stock or one of its competitors? The main competitors of Verve Therapeutics include Beam Therapeutics (BEAM), Krystal Biotech (KRYS), Cytokinetics (CYTK), Zai Lab (ZLAB), PTC Therapeutics (PTCT), Merus (MRUS), Arcellx (ACLX), ACADIA Pharmaceuticals (ACAD), SpringWorks Therapeutics (SWTX), and Ultragenyx Pharmaceutical (RARE). These companies are all part of the "pharmaceutical products" industry.
Verve Therapeutics vs. Its Competitors
Beam Therapeutics (NASDAQ:BEAM) and Verve Therapeutics (NASDAQ:VERV) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, institutional ownership, media sentiment, dividends, valuation and profitability.
Verve Therapeutics has a net margin of -303.64% compared to Beam Therapeutics' net margin of -609.24%. Verve Therapeutics' return on equity of -35.81% beat Beam Therapeutics' return on equity.
Beam Therapeutics has a beta of 2.07, suggesting that its share price is 107% more volatile than the S&P 500. Comparatively, Verve Therapeutics has a beta of 2.23, suggesting that its share price is 123% more volatile than the S&P 500.
Verve Therapeutics has lower revenue, but higher earnings than Beam Therapeutics. Verve Therapeutics is trading at a lower price-to-earnings ratio than Beam Therapeutics, indicating that it is currently the more affordable of the two stocks.
Beam Therapeutics presently has a consensus target price of $48.75, suggesting a potential upside of 140.15%. Verve Therapeutics has a consensus target price of $14.57, suggesting a potential upside of 30.92%. Given Beam Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Beam Therapeutics is more favorable than Verve Therapeutics.
99.7% of Beam Therapeutics shares are held by institutional investors. Comparatively, 97.1% of Verve Therapeutics shares are held by institutional investors. 3.5% of Beam Therapeutics shares are held by company insiders. Comparatively, 19.3% of Verve Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
In the previous week, Beam Therapeutics had 4 more articles in the media than Verve Therapeutics. MarketBeat recorded 7 mentions for Beam Therapeutics and 3 mentions for Verve Therapeutics. Beam Therapeutics' average media sentiment score of 0.50 beat Verve Therapeutics' score of 0.26 indicating that Beam Therapeutics is being referred to more favorably in the media.
Summary
Beam Therapeutics beats Verve Therapeutics on 10 of the 17 factors compared between the two stocks.
Get Verve Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for VERV and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding VERV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Verve Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:VERV) was last updated on 7/9/2025 by MarketBeat.com Staff
Free VERV Stock Alerts